BnR Summit 2026

Belt & Road Summit - Deal-Making 2026

9 – 15 Sept 2026 | Hong Kong, China (Hong Kong)

Register
Register
Register

ProjectUpdated on 28 July 2026

Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)

CEO at Shanghai Haiju Biotechnology Co., Ltd.

China

About

HJ-462 features protein kinase inhibitors with ingenious molecular designs that avoid defects in drug metabolism within the body, resulting in excellent safety and remarkable efficacy(achieving 100% tumor regression in liver cancer, gastric cancer, and lung cancer models caused by MET amplification, effectively curing these conditions).

Project Location

  • China

Project Format

  • Private Project

Go Global Project

  • Yes

ESG (Environmental, Social, and Governance)

  • Yes

Project Stage

  • Investment / Financing Discussion

Main Project Sector

  • Technology

Technology

  • Bio-Tech
  • Health Technology

Total Project Value

  • 5,000,001 to 7,500,000 USD

Investment Capital Required

  • 1,000,001 to 2,500,000 USD

Interested Format of Cooperation

  • Convertible Loan
  • Direct Equity Investment
  • Joint Venture
  • M&A / Strategic Acquisition Opportunity

Preferred Financing Model

  • Debt
  • Equity

Type(s) of Last Financing Round of the project (if Applicable)

  • Equity (private)

Main Service(s) Required

  • Financial Services

Similar opportunities